BioMarin Pharmaceutical | BMRN

Stock Price
87.22
Daily Change
-1.43%
Yearly
16.09%
Q2 Forecast
85.94
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 23.79 -0.99 -4.00% 47.31%
Acorda Therapeutics 0.61 0.02 2.93% 20.21%
Agios Pharmaceuticals 25.32 -0.50 -1.94% 30.05%
Alnylam Pharmaceuticals 186.46 -1.80 -0.96% 48.22%
Amgen 218.53 1.60 0.74% -14.88%
Bayer 53.42 -0.93 -1.71% -19.77%
Biogen 298.69 0.03 0.01% 49.35%
Bluebird Bio 3.31 -0.25 -7.02% 3.44%
BioMarin Pharmaceutical 87.22 -1.27 -1.43% 16.09%
Gilead Sciences 76.33 -0.76 -0.99% 17.70%
Intercept Pharmaceuticals 10.77 0.51 4.97% -40.50%
Incyte Corp 61.87 -0.71 -1.13% -18.47%
Insmed 18.69 -0.10 -0.53% -0.69%
Ionis Pharmaceuticals 40.55 -0.19 -0.47% 11.04%
Moderna 128.89 2.65 2.10% -11.31%
Neurocrine Biosciences 90.11 -1.11 -1.22% -3.62%
Puma Biotechnology 3.27 0.08 2.51% 68.56%
PTC Therapeutics 41.16 -1.50 -3.52% 40.14%
Ultragenyx Pharmaceutical 48.41 -1.42 -2.85% 3.22%
Regeneron Pharmaceuticals 728.60 3.55 0.49% 9.61%
Roche Holding 287.90 -2.80 -0.96% -11.80%
Seattle Genetics 194.01 0.52 0.27% 42.99%
Sangamo BioSciences 1.15 -0.12 -9.13% -68.63%
Sanofi 50.45 -2.06 -3.92% -5.26%
Sarepta Therapeutics 124.82 -2.00 -1.58% 71.41%
United Therapeutics 205.19 -2.13 -1.03% -10.92%
Vertex Pharmaceuticals 325.30 -4.69 -1.42% 21.09%

Indexes Price Day Year
USND 13017 41.74 0.32% 7.75%

BioMarin Pharmaceutical

BioMarin Pharmaceutical traded at $87.22 this Tuesday May 30th, decreasing $1.27 or 1.43 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical lost 10.06 percent. Over the last 12 months, its price rose by 16.09 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 85.94 by the end of this quarter and at 78.72 in one year, according to Trading Economics global macro models projections and analysts expectations.

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.